William F. Hahne
Corporate Officer/Principal at BIO-PATH HOLDINGS, INC.
Profile
William F.
Hahne is currently the Vice President-Clinical Research at Bio-Path Holdings, Inc. He previously worked as the Executive Director-Clinical Research at Eisai, Inc. from 1997 to 2002, Vice President-Clinical Development at CuraGen Corp.
from 2003 to 2005, VP-Clinical Development & Medical Affairs at Imunon, Inc. in 2006-2007, and Vice President-Medical at Vion Pharmaceuticals, Inc. He has an undergraduate degree from Grinnell College and a doctorate from Cornell University.
William F. Hahne active positions
| Companies | Position | Start |
|---|---|---|
| BIO-PATH HOLDINGS, INC. | Corporate Officer/Principal | - |
Former positions of William F. Hahne
| Companies | Position | End |
|---|---|---|
| IMUNON, INC. | Chief Tech/Sci/R&D Officer | 2007-11-30 |
CuraGen Corp.
 CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Chief Tech/Sci/R&D Officer | 2004-12-31 |
Eisai, Inc.
 Eisai, Inc. Pharmaceuticals: MajorHealth Technology Eisai, Inc. manufactures pharmaceuticals products. It focuses on neurology, gastrointestinal disorders and oncology critical care. The company was founded in 1995 and is headquartered in Woodcliff Lake, NJ. | Chief Tech/Sci/R&D Officer | 2001-12-31 |
Vion Pharmaceuticals, Inc.
 Vion Pharmaceuticals, Inc. BiotechnologyHealth Technology Vion Pharmaceuticals, Inc. develops therapeutics for the treatment of cancer. The company was founded in March 1992 and is headquartered in New Haven, CT. | Chief Tech/Sci/R&D Officer | - |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Chief Tech/Sci/R&D Officer | - |
Training of William F. Hahne
| Grinnell College | Undergraduate Degree |
| Cornell University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| IMUNON, INC. | Health Technology |
| BIO-PATH HOLDINGS, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Vion Pharmaceuticals, Inc.
Vion Pharmaceuticals, Inc. BiotechnologyHealth Technology Vion Pharmaceuticals, Inc. develops therapeutics for the treatment of cancer. The company was founded in March 1992 and is headquartered in New Haven, CT. | Health Technology |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Health Technology |
Eisai, Inc.
Eisai, Inc. Pharmaceuticals: MajorHealth Technology Eisai, Inc. manufactures pharmaceuticals products. It focuses on neurology, gastrointestinal disorders and oncology critical care. The company was founded in 1995 and is headquartered in Woodcliff Lake, NJ. | Health Technology |
- Stock Market
- Insiders
- William F. Hahne
